Chronic myeloid leukemia

CML · Oncology · 3 drugs · 3 indications

Competitive Landscape (3 drugs)
DrugCompanyMechanismModalityRouteStage
ScemblixNVSBCR-ABL inhibitor (STAMP)Small moleculeOralAPPROVED
TasignaNVSBCR-ABL inhibitor (STAMP)Small moleculeOralAPPROVED
IclusigBCR-ABL inhibitor (pan)Small moleculePOAPPROVED
Indications (3)
CML/Ph+ ALL with T315I
Iclusig APPROVED
CML
Tasigna APPROVED
Ph+ CML in chronic phase
Scemblix APPROVED
Upcoming Catalysts
Scemblix - 1L CML - FDA ApprovalREGULATORY
NVSH1 2026
Data from Supabase · Updated 2026-03-24